Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Muggia

Showing results (31-40 of 95) with videos related to

Pageof 10
Sort By:
Anticancer Research|January 10, 2014
Targeted agents and oxaliplatin-containing regimens for the treatment of colon cancerAndrea Bonetti, Jacopo Giuliani, Franco Muggia
Oncology (Williston Park, N.Y.)|June 7, 2005
Epidermal growth factor receptor inhibitors for the treatment of epithelial ovarian cancerStephanie V Blank, Richard Chang, Franco Muggia
Expert Opinion on Investigational Drugs|March 13, 2012
Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabineFranco Muggia, Isabela Diaz, Godefridus J Peters
Journal of the National Cancer Institute|December 1, 2010
Delayed neoplastic and renal complications in women receiving long-term chemotherapy for recurrent ovarian cancerFranco Muggia, Timothy Cannon, Tamar Safra, et al.
Cancer Chemotherapy and Pharmacology|March 9, 2018
Carboplatin (every 21 days) and divided-dose paclitaxel (days 1, 11): rationale and tolerance in chemotherapy naïve women with high-grade epithelial cancers of Mullerian originDavid Kudlowitz, Alejandro Velastegui, Fernanda Musa, et al.
Clinical Medicine. Oncology|September 6, 2011
Documentation of complete response in metastatic breast cancer to liver and bone achieved with trastuzumab and pegylated liposomal DoxorubicinBoris Kobrinsky, Eleni Andreopoulou, Karen Mourtzikos, et al.
The Oncologist|May 25, 2006
Topotecan continuous infusion: CA-125 responses including patients pretreated with other schedules of topotecanFranco Muggia, Rebecca Kosloff, Leonard Liebes, et al.
Advanced Drug Delivery Reviews|July 27, 2011
Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and preventionJanos Szebeni, Franco Muggia, Alberto Gabizon, et al.
International Journal of Hepatology|April 21, 2012
Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic originPing Gu, Jennifer Wu, Elliot Newman, et al.
Anticancer Research|November 27, 2008
Concurrent radiotherapy, paclitaxel and dose escalating carboplatin in the treatment of cervical cancer--a phase I studyDaniela Addeo, Stephanie Blank, Franco Muggia, et al.
Pageof 10

Showing results (31-40 of 95) with videos related to

Sort By:
Pageof 10
Anticancer Research|January 10, 2014
Targeted agents and oxaliplatin-containing regimens for the treatment of colon cancerAndrea Bonetti, Jacopo Giuliani, Franco Muggia
Oncology (Williston Park, N.Y.)|June 7, 2005
Epidermal growth factor receptor inhibitors for the treatment of epithelial ovarian cancerStephanie V Blank, Richard Chang, Franco Muggia
Expert Opinion on Investigational Drugs|March 13, 2012
Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabineFranco Muggia, Isabela Diaz, Godefridus J Peters
Journal of the National Cancer Institute|December 1, 2010
Delayed neoplastic and renal complications in women receiving long-term chemotherapy for recurrent ovarian cancerFranco Muggia, Timothy Cannon, Tamar Safra, et al.
Cancer Chemotherapy and Pharmacology|March 9, 2018
Carboplatin (every 21 days) and divided-dose paclitaxel (days 1, 11): rationale and tolerance in chemotherapy naïve women with high-grade epithelial cancers of Mullerian originDavid Kudlowitz, Alejandro Velastegui, Fernanda Musa, et al.
Clinical Medicine. Oncology|September 6, 2011
Documentation of complete response in metastatic breast cancer to liver and bone achieved with trastuzumab and pegylated liposomal DoxorubicinBoris Kobrinsky, Eleni Andreopoulou, Karen Mourtzikos, et al.
The Oncologist|May 25, 2006
Topotecan continuous infusion: CA-125 responses including patients pretreated with other schedules of topotecanFranco Muggia, Rebecca Kosloff, Leonard Liebes, et al.
Advanced Drug Delivery Reviews|July 27, 2011
Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and preventionJanos Szebeni, Franco Muggia, Alberto Gabizon, et al.
International Journal of Hepatology|April 21, 2012
Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic originPing Gu, Jennifer Wu, Elliot Newman, et al.
Anticancer Research|November 27, 2008
Concurrent radiotherapy, paclitaxel and dose escalating carboplatin in the treatment of cervical cancer--a phase I studyDaniela Addeo, Stephanie Blank, Franco Muggia, et al.
Pageof 10